XML 80 R82.htm IDEA: XBRL DOCUMENT
v3.19.3

Agreement with Eli Lilly and Company (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Agreement with Eli Lilly and Company |
Summary of deferred revenue included in the Company's balance sheets | As of September 30, 2019, deferred revenue included in the Company’s balance sheets comprised the following (in thousands):
|  | September 30, |  | December 31,
|  | 2019 |  | 2018
Deferred revenue, beginning of period |  | $ | 26,725 |  | $ | —
Up-front payment |  |  | — |  |  | 25,000
Attributed premium on the proceeds from Lilly’s investment in the Company |  |  | — |  |  | 1,725
Research and development support billing |  |  | 1,500 |  |  | —
Revenue from research and development arrangement recognized |  |  | (4,342) |  |  | —
Total deferred revenue, end of period |  |  | 23,883 |  |  | 26,725
Less: Deferred revenue, current portion |  |  | (6,199) |  |  | (4,989)
Deferred revenue, non-current portion |  | $ | 17,684 |  | $ | 21,736

X
- Definition N/A + References No definition available. + Details
Name: | nxtc_CollaborativeArrangementDisclosureAbstract
Namespace Prefix: | nxtc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the tabular disclosure of deferred revenue from related party. + References No definition available. + Details
Name: | nxtc_ScheduleOfDeferredRevenueFromRelatedPartyTableTextBlock
Namespace Prefix: | nxtc_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration